The latest data from the winter's record-breaking Covid-19 surge shows that the anti-vaccines and booster shots may be less effective at defending against the omicron variant.
The coronaviruses mass vaccine centre is located at the Edinburgh International Conference Centre in Edinburgh, Scotland.
When the omicron variant accounted for most of the Covid-19 cases, the study examined the antibodies of 18 vaccine recipients and boosted them.
The researchers found that the patients had high levels of antibodies that stopped the coronaviruses spike from binding to the cells, but they didn't carry out that function when responding to the omicron strain.
The study compared the immune system responses of people who had been exposed to the coronaviruses and people who hadn't, and found that both groups had the same levels of antibodies.
The results are different from earlier studies that showed people who had contracted the virus had lower levels of immunity.
The study found that patients with breakthrough cases of omicron produced strong responses to their immune cells, which may explain why some people experience mild Covid-19 symptoms.
58.7%. According to data released by the CDC Tuesday, the number of Americans who tested positive for coronaviruses in February was up from 33.5% in December. Three-in-four children have had Covid-19 at some point, according to a study. The country's record-breaking winter surge resulted in a huge jump in natural antibodies.
Moderna began phase 2 trials of its booster shot last month, and Pfizer is also developing omicron-specific vaccine booster boosters that could potentially produce better-equipped to counter the variant. Albert Bourla, the CEO of Pfizer, said earlier this month that he hopes the vaccine will be ready by the fall.
Live updates on the coronaviruses.
All Rights Reserved © 2024
